The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Oncology Market Research Report 2024
Synopsis
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
The global Drugs for Oncology market was valued at US$ 197440 million in 2023 and is anticipated to reach US$ 342140 million by 2030, witnessing a CAGR of 8.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Oncology.
Report Scope
The Drugs for Oncology market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Oncology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
The global Drugs for Oncology market was valued at US$ 197440 million in 2023 and is anticipated to reach US$ 342140 million by 2030, witnessing a CAGR of 8.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Oncology.
Report Scope
The Drugs for Oncology market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Oncology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Oncology Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Drugs for Oncology Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Oncology Market Perspective (2019-2030)
2.2 Drugs for Oncology Growth Trends by Region
2.2.1 Global Drugs for Oncology Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs for Oncology Historic Market Size by Region (2019-2024)
2.2.3 Drugs for Oncology Forecasted Market Size by Region (2025-2030)
2.3 Drugs for Oncology Market Dynamics
2.3.1 Drugs for Oncology Industry Trends
2.3.2 Drugs for Oncology Market Drivers
2.3.3 Drugs for Oncology Market Challenges
2.3.4 Drugs for Oncology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Oncology Players by Revenue
3.1.1 Global Top Drugs for Oncology Players by Revenue (2019-2024)
3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2019-2024)
3.2 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Oncology Revenue
3.4 Global Drugs for Oncology Market Concentration Ratio
3.4.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2023
3.5 Drugs for Oncology Key Players Head office and Area Served
3.6 Key Players Drugs for Oncology Product Solution and Service
3.7 Date of Enter into Drugs for Oncology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Oncology Breakdown Data by Type
4.1 Global Drugs for Oncology Historic Market Size by Type (2019-2024)
4.2 Global Drugs for Oncology Forecasted Market Size by Type (2025-2030)
5 Drugs for Oncology Breakdown Data by Application
5.1 Global Drugs for Oncology Historic Market Size by Application (2019-2024)
5.2 Global Drugs for Oncology Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs for Oncology Market Size (2019-2030)
6.2 North America Drugs for Oncology Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs for Oncology Market Size by Country (2019-2024)
6.4 North America Drugs for Oncology Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Oncology Market Size (2019-2030)
7.2 Europe Drugs for Oncology Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs for Oncology Market Size by Country (2019-2024)
7.4 Europe Drugs for Oncology Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Oncology Market Size (2019-2030)
8.2 Asia-Pacific Drugs for Oncology Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs for Oncology Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs for Oncology Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Oncology Market Size (2019-2030)
9.2 Latin America Drugs for Oncology Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs for Oncology Market Size by Country (2019-2024)
9.4 Latin America Drugs for Oncology Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Oncology Market Size (2019-2030)
10.2 Middle East & Africa Drugs for Oncology Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs for Oncology Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs for Oncology Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Drugs for Oncology Introduction
11.1.4 Roche Revenue in Drugs for Oncology Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Detail
11.2.2 Celgene Business Overview
11.2.3 Celgene Drugs for Oncology Introduction
11.2.4 Celgene Revenue in Drugs for Oncology Business (2019-2024)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Drugs for Oncology Introduction
11.3.4 Novartis Revenue in Drugs for Oncology Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
11.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Drugs for Oncology Introduction
11.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Detail
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Drugs for Oncology Introduction
11.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2019-2024)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Drugs for Oncology Introduction
11.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2019-2024)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Drugs for Oncology Introduction
11.8.4 Pfizer Revenue in Drugs for Oncology Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Drugs for Oncology Introduction
11.9.4 Amgen Revenue in Drugs for Oncology Business (2019-2024)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Drugs for Oncology Introduction
11.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2019-2024)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Drugs for Oncology Introduction
11.11.4 AbbVie Revenue in Drugs for Oncology Business (2019-2024)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Detail
11.12.2 Takeda Business Overview
11.12.3 Takeda Drugs for Oncology Introduction
11.12.4 Takeda Revenue in Drugs for Oncology Business (2019-2024)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Detail
11.13.2 Astellas Business Overview
11.13.3 Astellas Drugs for Oncology Introduction
11.13.4 Astellas Revenue in Drugs for Oncology Business (2019-2024)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Detail
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Drugs for Oncology Introduction
11.14.4 Ipsen Revenue in Drugs for Oncology Business (2019-2024)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Drugs for Oncology Introduction
11.15.4 Sanofi Revenue in Drugs for Oncology Business (2019-2024)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Detail
11.16.2 Bayer Business Overview
11.16.3 Bayer Drugs for Oncology Introduction
11.16.4 Bayer Revenue in Drugs for Oncology Business (2019-2024)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Detail
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Drugs for Oncology Introduction
11.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2019-2024)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Detail
11.18.2 Teva Business Overview
11.18.3 Teva Drugs for Oncology Introduction
11.18.4 Teva Revenue in Drugs for Oncology Business (2019-2024)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Detail
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Drugs for Oncology Introduction
11.19.4 Otsuka Revenue in Drugs for Oncology Business (2019-2024)
11.19.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Detail
11.20.2 Eisai Business Overview
11.20.3 Eisai Drugs for Oncology Introduction
11.20.4 Eisai Revenue in Drugs for Oncology Business (2019-2024)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Detail
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Drugs for Oncology Introduction
11.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2019-2024)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Detail
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Drugs for Oncology Introduction
11.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2019-2024)
11.22.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
